LIPO fundamentals
Key facts
Market capitalization—
Founded—
CEO—
Website—
About
Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
Dividends
Dividend yield, history and sustainability
LIPO does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company